Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Summary<br />
• In multivariate analyses:<br />
– ZOL treatment and high PgR expression associated with<br />
improved DFS and RFS<br />
– Lymph node involvement, high tumor grade, and large<br />
tumors associated with poor DFS and RFS<br />
• ZOL significantly improves clinical outcomes beyond<br />
those achieved with endocrine therapy alone<br />
–� Risk of DFS events by 36% (HR = 0.64; P = .012)<br />
–� Risk of RFS events by 35% (HR = 0.65; P = .014)<br />
–� improved OS (HR = 0.60; P = .10)<br />
–� Risk for bone metastases (HR = 0.68; P = .224)<br />
17
Change language